Literature DB >> 25281655

Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF.

Priyesh A Patel1, Gretchen Heizer2, Christopher M O'Connor2, Phillip J Schulte2, Kenneth Dickstein2, Justin A Ezekowitz2, Paul W Armstrong2, Vic Hasselblad2, Roger M Mills2, John J V McMurray2, Randall C Starling2, W H Wilson Tang2, Robert M Califf2, Adrian F Hernandez2.   

Abstract

BACKGROUND: Outcomes associated with episodes of hypotension while hospitalized with acute decompensated heart failure are not well understood. METHODS AND
RESULTS: Using data from Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF), we assessed factors associated with in-hospital hypotension and subsequent 30-day outcomes. Patients were classified as having symptomatic or asymptomatic hypotension. Multivariable logistic regression was used to determine factors associated with in-hospital hypotension, and Cox proportional hazards models were used to assess the association between hypotension and 30-day outcomes. We also tested for treatment interaction with nesiritide on 30-day outcomes and the association between in-hospital hypotension and renal function at hospital discharge. Overall, 1555 of 7141 (21.8%) patients had an episode of hypotension, of which 73.1% were asymptomatic and 26.9% were symptomatic. Factors strongly associated with in-hospital hypotension included randomization to nesiritide (odds ratio, 1.98; 95% confidence interval [CI], 1.76-2.23; P<0.001), chronic metolazone therapy (odds ratio, 1.74; 95% CI, 1.17-2.60; P<0.001), and baseline orthopnea (odds ratio, 1.31; 95% CI, 1.13-1.52; P=0.001) or S3 gallop (odds ratio, 1.21; 95% CI, 1.06-1.40; P=0.006). In-hospital hypotension was associated with increased hazard of 30-day mortality (hazard ratio, 2.03; 95% CI, 1.57-2.61; P<0.001), 30-day heart failure hospitalization or mortality (hazard ratio, 1.58; 95% CI, 1.34-1.86; P<0.001), and 30-day all-cause hospitalization or mortality (hazard ratio, 1.40; 95% CI, 1.22-1.61; P<0.001). Nesiritide had no interaction on the relationship between hypotension and 30-day outcomes (interaction P=0.874 for death, P=0.908 for death/heart failure hospitalization, P=0.238 death/all-cause hospitalization).
CONCLUSIONS: Hypotension while hospitalized for acute decompensated heart failure is an independent risk factor for adverse 30-day outcomes, and its occurrence highlights the need for modified treatment strategies. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00475852.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  heart failure; hypotension; natriuretic peptide, brain

Mesh:

Substances:

Year:  2014        PMID: 25281655      PMCID: PMC4456178          DOI: 10.1161/CIRCHEARTFAILURE.113.000872

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  22 in total

Review 1.  Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure.

Authors:  Mihai Gheorghiade; Muthiah Vaduganathan; Andrew Ambrosy; Michael Böhm; Umberto Campia; John G F Cleland; Francesco Fedele; Gregg C Fonarow; Aldo P Maggioni; Alexandre Mebazaa; Mandeep Mehra; Marco Metra; Savina Nodari; Peter S Pang; Piotr Ponikowski; Hani N Sabbah; Michel Komajda; Javed Butler
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

2.  Risk stratification after hospitalization for decompensated heart failure.

Authors:  G Michael Felker; Jeffrey D Leimberger; Robert M Califf; Michael S Cuffe; Barry M Massie; Kirkwood F Adams; Mihai Gheorghiade; Christopher M O'Connor
Journal:  J Card Fail       Date:  2004-12       Impact factor: 5.712

3.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.

Authors:  Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade
Journal:  JAMA       Date:  2002-03-27       Impact factor: 56.272

4.  Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis.

Authors:  Gregg C Fonarow; Kirkwood F Adams; William T Abraham; Clyde W Yancy; W John Boscardin
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

5.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

6.  Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure.

Authors:  W Franklin Peacock; Charles L Emerman; Marc A Silver
Journal:  Am J Emerg Med       Date:  2005-05       Impact factor: 2.469

7.  Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.

Authors:  Mihai Gheorghiade; William T Abraham; Nancy M Albert; Barry H Greenberg; Christopher M O'Connor; Lilin She; Wendy Gattis Stough; Clyde W Yancy; James B Young; Gregg C Fonarow
Journal:  JAMA       Date:  2006-11-08       Impact factor: 56.272

8.  Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.

Authors:  John E A Blair; Faiez Zannad; Marvin A Konstam; Thomas Cook; Brian Traver; John C Burnett; Liliana Grinfeld; Holly Krasa; Aldo P Maggioni; Cesare Orlandi; Karl Swedberg; James E Udelson; Christopher Zimmer; Mihai Gheorghiade
Journal:  J Am Coll Cardiol       Date:  2008-11-11       Impact factor: 24.094

9.  Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).

Authors:  Adrian F Hernandez; Christopher M O'Connor; Randall C Starling; Craig J Reist; Paul W Armstrong; Kenneth Dickstein; Todd J Lorenz; W Brian Gibler; Vic Hasselblad; Michel Komajda; Barry Massie; John J V McMurray; Markku Nieminen; Jean L Rouleau; Karl Swedberg; Robert M Califf
Journal:  Am Heart J       Date:  2008-12-19       Impact factor: 4.749

10.  Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial.

Authors:  Clyde W Yancy; Henry Krum; Barry M Massie; Marc A Silver; Lynne Warner Stevenson; Mei Cheng; Sun Sook Kim; Rosemary Evans
Journal:  Circ Heart Fail       Date:  2008-05       Impact factor: 8.790

View more
  14 in total

1.  Effect of carperitide on in-hospital mortality of patients admitted for heart failure: propensity score analyses.

Authors:  Masataka Ogiso; Toshiaki Isogai; Yuta Okabe; Kansuke Ito; Masaki Tsuji; Hiroyuki Tanaka
Journal:  Heart Vessels       Date:  2017-02-20       Impact factor: 2.037

2.  Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.

Authors:  Poghni A Peri-Okonny; Xiaojuan Mi; Yevgeniy Khariton; Krishna K Patel; Laine Thomas; Gregg C Fonarow; Puza P Sharma; Carol I Duffy; Nancy M Albert; Javed Butler; Adrian F Hernandez; Kevin McCague; Fredonia B Williams; Adam D DeVore; J Herbert Patterson; John A Spertus
Journal:  JACC Heart Fail       Date:  2019-02-06       Impact factor: 12.035

3.  Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF.

Authors:  Amanda K Verma; Jie-Lena Sun; Adrian Hernandez; John R Teerlink; Phillip J Schulte; Justin Ezekowitz; Adriaan Voors; Randall Starling; Paul Armstrong; Christopher M O'Conner; Robert J Mentz
Journal:  Clin Cardiol       Date:  2018-07-17       Impact factor: 2.882

4.  Pre-clinical model of severe glutathione peroxidase-3 deficiency and chronic kidney disease results in coronary artery thrombosis and depressed left ventricular function.

Authors:  Paul Pang; Molly Abbott; Malyun Abdi; Quynh-Anh Fucci; Nikita Chauhan; Murti Mistri; Brandon Proctor; Matthew Chin; Bin Wang; Wenqing Yin; Tzong-Shi Lu; Arvin Halim; Kenneth Lim; Diane E Handy; Joseph Loscalzo; Andrew M Siedlecki
Journal:  Nephrol Dial Transplant       Date:  2018-06-01       Impact factor: 5.992

5.  Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF.

Authors:  Gad Cotter; Beth A Davison; Javed Butler; Sean P Collins; Justin A Ezekowitz; G Michael Felker; Gerasimos Filippatos; Phillip D Levy; Marco Metra; Piotr Ponikowski; John R Teerlink; Adriaan A Voors; Stefanie Senger; David Bharucha; Kathleen Goin; David G Soergel; Peter S Pang
Journal:  Clin Res Cardiol       Date:  2017-10-06       Impact factor: 5.460

6.  Pharmacological interventions for heart failure in people with chronic kidney disease.

Authors:  Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

7.  Acute decompensated heart failure in the emergency department: Identification of early predictors of outcome.

Authors:  Luigi Mario Castello; Luca Molinari; Alessandra Renghi; Elena Peruzzi; Andrea Capponi; Gian Carlo Avanzi; Mario Pirisi
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

8.  Treatment patterns of patients with acute heart failure who develop acute kidney injury.

Authors:  Jubran Boulos; Wisam Darawsha; Zaid A Abassi; Zaher S Azzam; Doron Aronson
Journal:  ESC Heart Fail       Date:  2018-12-19

Review 9.  Acute heart failure management in the USA and Japan: overview of practice patterns and review of evidence.

Authors:  Toshikazu D Tanaka; Mitsuaki Sawano; Ravi Ramani; Mark Friedman; Shun Kohsaka
Journal:  ESC Heart Fail       Date:  2018-06-22

10.  Impact of early treatment with intravenous vasodilators and blood pressure reduction in acute heart failure.

Authors:  Takeshi Kitai; W H Wilson Tang; Andrew Xanthopoulos; Ryosuke Murai; Takafumi Yamane; Kitae Kim; Shogo Oishi; Eiichi Akiyama; Satoshi Suzuki; Masayoshi Yamamoto; Keisuke Kida; Takahiro Okumura; Shuichiro Kaji; Yutaka Furukawa; Yuya Matsue
Journal:  Open Heart       Date:  2018-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.